Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Dow
McKinsey
Merck

Last Updated: June 25, 2022

CLINICAL TRIALS PROFILE FOR HYALURONIDASE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for HYALURONIDASE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01839487 ↗ PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Completed Halozyme Therapeutics Phase 2 2013-05-14 This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). The study will have 2 run-in phases, one for each formulation of PEGPH20 (original and new formulations), and a Phase 2 portion. The 2 run-in phases will evaluate the safety and tolerability of the PAG treatment using the original and new succinic acid PEGPH20 formulation, respectively, compared with AG treatment. Phase 2 will have 2 stages due to a partial clinical hold that occurred from April through July 2014. The participants will be randomized in 3:1 for the run-in phases. The first stage will randomize participants in a 1:1 ratio. The second stage will randomize participants in a 2:1 ratio (PAG:AG). This is an open-label study. To minimize bias to the progression-free survival endpoint, disease progression will be based on the assessment of the Central Imaging Reader (CIR). Determination of clinical progression by the Investigator without corresponding CIR confirmation will be documented with the relevant signs and symptoms.
New Formulation NCT05388669 ↗ A Study of Lazertinib and Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer Not yet recruiting Janssen Research & Development, LLC Phase 3 2022-08-05 The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for HYALURONIDASE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000493 ↗ Multicenter Investigation of Limitation of Infarct Size (MILIS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1977-09-01 To assess the ability of two separate therapeutic interventions, propranolol and hyaluronidase, to limit the ultimate size of an acute myocardial infarction. A secondary objective was to assess the influence of these therapies upon ventricular function and morbidity following myocardial infarction.
NCT00198419 ↗ Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Completed Bausch & Lomb Incorporated Phase 1 2004-03-01 The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
NCT00198458 ↗ Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Completed Bausch & Lomb Incorporated Phase 1 2004-07-01 The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.
NCT00198471 ↗ Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed Bausch & Lomb Incorporated Phase 2 2005-07-01 The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
NCT00198484 ↗ Evaluation of Vitrase as a Spreading Agent Completed Bausch & Lomb Incorporated Phase 3 2004-10-01 The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for HYALURONIDASE

Condition Name

Condition Name for HYALURONIDASE
Intervention Trials
Healthy 6
Type 1 Diabetes Mellitus 6
Dehydration 5
Multiple Myeloma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for HYALURONIDASE
Intervention Trials
Diabetes Mellitus 12
Diabetes Mellitus, Type 1 9
Neoplasms, Plasma Cell 7
Multiple Myeloma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for HYALURONIDASE

Trials by Country

Trials by Country for HYALURONIDASE
Location Trials
United States 401
United Kingdom 16
France 15
Spain 14
Brazil 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for HYALURONIDASE
Location Trials
California 34
New York 21
Texas 19
Washington 18
North Carolina 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for HYALURONIDASE

Clinical Trial Phase

Clinical Trial Phase for HYALURONIDASE
Clinical Trial Phase Trials
Phase 4 15
Phase 3 18
Phase 2/Phase 3 2
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for HYALURONIDASE
Clinical Trial Phase Trials
Completed 56
Recruiting 17
Not yet recruiting 10
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HYALURONIDASE

Sponsor Name

Sponsor Name for HYALURONIDASE
Sponsor Trials
Halozyme Therapeutics 36
National Cancer Institute (NCI) 7
Baxter Healthcare Corporation 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for HYALURONIDASE
Sponsor Trials
Industry 72
Other 71
NIH 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Moodys
Express Scripts
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.